Peptides Similar to GLP-1

Compounds Related to GLP-1#

GLP-1 sits at the center of a rapidly expanding therapeutic landscape. Understanding the relationships between native GLP-1, its analogs, and related incretins provides context for one of the most dynamic areas of drug development in modern medicine.

Semaglutide -- The Weekly GLP-1 Analog#

Semaglutide (Ozempic, Wegovy, Rybelsus) is currently the most commercially successful GLP-1 receptor agonist. Developed by Novo Nordisk, semaglutide achieves a 7-day half-life through two key modifications: substitution of Aib (alpha-aminoisobutyric acid) at position 8 to prevent DPP-4 cleavage, and attachment of a C18 fatty diacid through a linker at position 26 that enables strong albumin binding. These modifications extend the half-life from 1-2 minutes (native GLP-1) to approximately 168 hours.

Semaglutide has demonstrated superior efficacy compared to earlier GLP-1 RAs in head-to-head trials, with HbA1c reductions of 1.5-1.8% and weight loss of 10-15% in diabetes trials. At the higher obesity dose (2.4 mg weekly), weight loss averages approximately 15%. The oral formulation (Rybelsus) uses a permeation enhancer (SNAC) to enable gastrointestinal absorption, though with lower bioavailability and somewhat reduced efficacy compared to injection.

Liraglutide -- The First Major GLP-1 Analog#

Liraglutide was the GLP-1 analog that truly established the class as a mainstream therapy. Its once-daily dosing, significant weight loss benefit, and cardiovascular protection (LEADER trial) made it the reference standard against which newer agents are compared. Liraglutide is 97% homologous to native GLP-1, with a single amino acid substitution (Arg34 to Lys) and a C16 palmitic acid attached via a glutamic acid spacer at position 26.

Tirzepatide -- The Dual Agonist#

Tirzepatide (Mounjaro, Zepbound) represents a paradigm shift from GLP-1 mono-agonism to dual incretin agonism. Based on the GIP sequence backbone with engineered GLP-1 receptor activity, tirzepatide activates both the GIP and GLP-1 receptors. In clinical trials, tirzepatide has produced greater weight loss and HbA1c reduction than semaglutide, suggesting that engaging both incretin pathways provides additive or synergistic metabolic benefit.

Exenatide -- The First-in-Class#

Exenatide (Byetta, Bydureon) was the first approved GLP-1 receptor agonist, based on exendin-4 — a peptide isolated from Gila monster venom that shares 53% sequence identity with human GLP-1 but is naturally DPP-4 resistant. While now largely superseded by longer-acting agents, exenatide pioneered the GLP-1 RA class and demonstrated the feasibility of incretin-based therapy.

GIP (Glucose-Dependent Insulinotropic Polypeptide)#

GIP is the other major incretin hormone, produced by intestinal K-cells. It was originally thought to be a less attractive therapeutic target because GIP receptor agonism alone has limited efficacy in type 2 diabetes (due to GIP resistance in the diabetic state). However, tirzepatide's success has reignited interest in GIP biology and suggests that combined GIP/GLP-1 agonism may overcome GIP resistance.

DPP-4 Inhibitors#

DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) take an indirect approach: by blocking the enzyme that degrades endogenous GLP-1, they increase circulating active GLP-1 levels 2-3 fold. While safer and orally available, DPP-4 inhibitors produce more modest HbA1c reductions (0.5-0.8%) and minimal weight loss compared to GLP-1 RAs, because they can only amplify the body's own GLP-1 production rather than achieving supraphysiological receptor stimulation.

Comparative Summary#

Related Reading#

• GLP-1 overview and research guide
• GLP-1 research evidence
• GLP-1 dosing protocols